세계의 섬유선종 시장 : 유형, 진단, 치료, 최종사용자 및 지역별 예측(-2032년)

Global Fibroadenoma Market Research Report Information by Type, by Diagnosis & Treatment, by End User and by Region - Forecast till 2032

US $ 4,950 ￦ 6,904,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 5,950 ￦ 8,299,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 7,250 ￦ 10,113,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업이 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능하며, 인쇄 가능합니다.

한글목차

섬유선종 시장 규모는 2023년 7억 1,000만 달러, 2024년 7억 7,000만 달러에서 예측 기간 동안 6.36%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 13억 4,000만 달러 규모로 성장할 것으로 예측됩니다.

여성의 섬유선종 발병률 증가와 공공 교육 캠페인을 통한 섬유선종에 대한 인식 개선이 섬유수종 시장의 성장을 가속하는 주요 요인으로 작용하고 있습니다.

섬유선종에 대한 인지도를 높이기 위한 공공 교육 캠페인은 섬유선종 시장 성장의 중요한 요인입니다. 대중 교육 캠페인은 여성들에게 섬유선종의 징후와 증상에 대해 알리는 데 필수적입니다. 이러한 인식 개선은 여성들이 정기적인 유방 검진 및 검진을 실시하도록 동기를 부여하고 적극적인 건강 추구 행동을 촉진할 수 있습니다. 섬유선종의 신속한 개입과 적절한 관리는 조기 발견에 달려있습니다. 또한 대중을 대상으로 한 교육 캠페인은 유방 덩어리에 대한 오해를 해소하고 이러한 발견에 종종 수반되는 불안과 두려움을 줄이는 데 도움이 될 수 있습니다.

섬유선종 시장의 확대는 진단 방법의 발전에도 큰 영향을 받고 있습니다. 적시에 적절한 의료 개입에 필수적인 진단 도구의 발전으로 탐지 정확도가 크게 향상되었습니다. 섬유선종의 정확한 식별은 필수적입니다. 의료 전문가들은 향상된 진단 기술을 통해 섬유선종을 조기에 발견할 수 있게 되었습니다. 적시에 적절한 치료 전략을 시행하고, 합병증 발생 가능성을 줄이고, 환자의 예후를 개선하기 위해서는 조기 진단이 매우 중요합니다. 자기공명영상(MRI), 초음파 등 비침습적 영상진단 기술의 도입과 개선으로 섬유선종 진단 접근법이 변화하고 있습니다.

세계 섬유선종(Fibroadenoma) 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 영향을 미치는 요인과 시장 기회 분석, 시장 규모 추이와 예측, 각종 부문별/지역별/주요 국가별 분석, 경쟁 환경, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

• 개요
• 성장 촉진요인
• 성장 억제요인
• 기회
• 과제
• COVID-19의 영향 분석

제5장 시장 요인 분석

• 밸류체인 분석
• Porter의 Five Forces 분석

제6장 세계의 섬유선종 시장 : 유형별

• 단순 섬유선종
• 복잡 섬유선종

제7장 세계의 섬유선종 시장 : 진단 및 치료별

• 진단
  • 초음파 스캔
  • 맘모그래피
  • 생검
• 치료
  • CRYOBLATION
  • HIGH INTENSITY FOCUSED ULTRASOUND (HIFU)
  • LUMPECTOMY
  • 약제

제8장 세계의 섬유선종 시장 : 최종사용자별

• 병원 및 진료소
• 진단센터
• 기타

제9장 세계의 섬유선종 시장 : 지역별

• 개요
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제10장 경쟁 구도

• 경쟁 대시보드
• 시장 점유율 분석
• 공개 기업 주식 개요
• 주요 전개와 성장 전략

제11장 기업 개요

• GE HEALTHCARE
• KONINKLIJKE PHILIPS N.V.
• SHIMADZU CORPORATION
• SIEMENS HEALTHINEERS
• CANON MEDICAL SYSTEMS CORPORATION
• DILON TECHNOLOGIES
• PFIZER, INC
• ICECURE MEDICAL
• ALPINION MEDICAL SYSTEMS
• FUJIFILM HOLDINGS CORPORATION

제12장 부록

• 참고 문헌
• 관련 보고서

LSH

영문 목차

영문목차

Global Fibroadenoma Market Research Report Information by Type (Simple Fibroadenoma and Complex Fibroadenoma), by Diagnosis & Treatment (Diagnosis [Ultrasound Scan, Mammography, and Biopsy] and Treatment [Cryoablation, High Intensity Focused Ultrasound (HIFU), Lumpectomy, and Drugs {Dydrogesterone, Medroxyprogesterone, Selective Estrogen Receptor Modulators, and Others}], by End User (Hospital and Clinics, Diagnostic Centers, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market overview

In 2023, the fibroadenoma market was estimated to be worth USD 0.71 billion. During the forecast period (2024-2032), the Fibroadenoma Market industry is anticipated to experience a compound annual growth rate (CAGR) of 6.36%, increasing from USD 0.77 billion in 2024 to USD 1.34 billion by 2032.

Rising incidences of fibroadenoma among women and increased awareness of fibroadenoma through public education campaigns are the primary factors propelling the growth of the fibroedema market.

Public education campaigns that aim to raise awareness of fibroadenoma are a significant factor in the growth of the fibroadenoma market. Public education campaigns are essential for informing women about the signs and symptoms of fibroadenoma. This increased awareness motivates women to undertake routine breast examinations and screenings and promotes proactive health-seeking behavior. The expeditious intervention and appropriate management of fibroadenomas are contingent upon early detection. Additionally, public education campaigns assist in the debunking of myths and misconceptions regarding breast lumps, thereby reducing the anxiety and dread that are often associated with such discoveries.

Additionally, the expansion of the fibroadenoma market is significantly influenced by the advancement of diagnostic methods. The precision of detection has been substantially improved by advancements in diagnostic tools, which are essential for timely and appropriate medical intervention. Accurate identification of fibroadenomas is essential. Healthcare professionals can identify fibroadenomas at an earlier stage with the assistance of improved diagnostic techniques. There is a critical need for early identification in order to implement treatment strategies that are timely and targeted, reduce the likelihood of complications, and improve patient outcomes. The diagnostic approach to fibroadenomas has been transformed by the introduction and refinement of non-invasive imaging technologies, including magnetic resonance imaging (MRI) and ultrasound.

Market segment insights

The Fibroadenoma Market is segmented into simple and complex fibroadenoma based on type.

The fibroadenoma market is segmented into 2 categories: diagnosis and treatment.

The fibroadenoma market is segmented into hospitals & clinics, ambulatory surgical centers, and others based on the end user.

Regional Perspectives

In 2022, North America held the largest market share of over 38.49% due to the advanced diagnostic techniques, medical infrastructure, and reimbursement policies and insurance coverage. Additionally, North Americans are more cognizant of health concerns and have greater access to healthcare than other regions. Even in cases where fibroadenomas are asymptomatic, this results in more frequent exams and diagnoses.

The fibroadenoma market in Europe is expected to experience substantial growth during the forecast year, 2024-2032, because of the growing emphasis on minimally invasive procedures for fibroadenomas, such as cryoablation and vacuum-assisted excision, which are particularly prevalent in Europe. The region's hospitals and institutions are well-equipped to perform these procedures, which attract patients who are interested in less invasive alternatives.

The Asia-Pacific fibroadenoma market is the fastest-growing region during the forecast period because of the frequent introduction of breast diagnosis and treatment devices through expansion. IceCure Medical Ltd. announced in May 2023 that ProSense had been installed and inaugurated at Kovai Medical Center and Hospital ("KMCH") in India.

Major Players

GE Healthcare (US), Koninklijke Philips N.V. (Germany), Shimadzu Corporation (Japan), Siemens Healthineers (Germany), Canon Medical Systems Corporation (Japan), Dilon Technologies (US), Pfizer, Inc. (US), IceCure Medical (Israel), Alpinion Medical Systems (South Korea), and Fujifilm Holdings Corporation (Japan) are among the key companies in the fibroadenoma market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TECHNIQUE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASED AWARENESS ABOUT FIBROADENOMA THROUGH PUBLIC EDUCATION CAMPAIGNS
  • 4.2.2 DEVELOPMENT OF IMPROVED DIAGNOSTIC TECHNIQUES TO ACCURATELY IDENTIFY FIBROADENOMA
  • 4.2.3 INCREASING PREVALENCE OF FIBROADENOMA AMONG WOMEN
• 4.3 RESTRAINTS
  • 4.3.1 HIGH COST OF TREATMENT OF FIBROADENOMA
• 4.4 OPPORTUNITY
  • 4.4.1 RESEARCH INTO NEW TREATMENT OPTIONS FOR FIBROADENOMA, SUCH AS MINIMALLY INVASIVE SURGICAL PROCEDURES OR MEDICATIONS
  • 4.4.2 GROWING ADOPTION OF MINIMALLY INVASIVE SURGICAL PROCEDURES FOR THE TREATMENT OF FIBROADENOMA
• 4.5 CHALLENGES
  • 4.5.1 NON-LIFE THREATENING NATURE OF FIBROADENOMAS
• 4.6 IMPACT ANALYSIS OF COVID-19
  • 4.6.1 IMPACT 0N OVERALL FIBROADENOMA INDUSTRY
    • 4.6.1.1 ECONOMIC IMPACT
  • 4.6.2 IMPACT ON GLOBAL FIBROADENOMA MARKET
  • 4.6.3 IMPACT ON THE SUPPLY CHAIN OF FIBROADENOMA
  • 4.6.4 IMPACT ON MARKET DEMAND OF FIBROADENOMA
    • 4.6.4.1 IMPACT DUE TO RESTRICTIONS/LOCKDOWN
    • 4.6.4.2 CONSUMER SENTIMENTS
  • 4.6.5 IMPACT ON PRICING OF FIBROADENOMA

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 RAW MATERIALS
  • 5.1.2 MANUFACTURING / PRODUCTION/ PROCESSING
  • 5.1.3 DISTRIBUTION CHANNEL
  • 5.1.4 END-USER
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 BARGAINING POWER OF SUPPLIERS
  • 5.2.2 BARGAINING POWER OF BUYERS
  • 5.2.3 THREAT OF NEW ENTRANTS
  • 5.2.4 THREAT OF SUBSTITUTES
  • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL FIBROADENOMA MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 SIMPLE FIBROADENOMA
• 6.3 COMPLEX FIBROADENOMA

7 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT

• 7.1 INTRODUCTION
• 7.2 DIAGNOSIS
  • 7.2.1 ULTRASOUND SCAN
  • 7.2.2 MAMMOGRAPHY
  • 7.2.3 BIOPSY
• 7.3 TREATMENT
  • 7.3.1 CRYOBLATION
  • 7.3.2 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU)
  • 7.3.3 LUMPECTOMY
  • 7.3.4 DRUGS
    • 7.3.4.1 DYDROGESTERONE
    • 7.3.4.2 MEDROXYPROGESTERONE
    • 7.3.4.3 SELECTIVE ESTROGEN RECEPTOR MODULATORS
    • 7.3.4.4 OTHERS

8 GLOBAL FIBROADENOMA MARKET, BY END-USER

• 8.1 INTRODUCTION
• 8.2 HOSPITAL AND CLINICS
• 8.3 DIAGNOSTIC CENTERS
• 8.4 OTHERS

9 GLOBAL FIBROADENOMA MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
  • 9.2.3 MEXICO
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 SPAIN
  • 9.3.5 ITALY
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 SOUTH AMERICA
  • 9.5.2 MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 COMPETITION DASHBOARD
• 10.3 MARKET SHARE ANALYSIS,
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.5.1 PRODUCT LAUNCH
  • 10.5.2 PARTNERSHIP
  • 10.5.3 EXPANSION

11 COMPANY PROFILES

• 11.1 GE HEALTHCARE
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGY
• 11.2 KONINKLIJKE PHILIPS N.V.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGY
• 11.3 SHIMADZU CORPORATION
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGY
• 11.4 SIEMENS HEALTHINEERS
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGY
• 11.5 CANON MEDICAL SYSTEMS CORPORATION
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 SWOT ANALYSIS
  • 11.5.5 KEY DEVELOPMENTS
  • 11.5.6 KEY STRATEGY
• 11.6 DILON TECHNOLOGIES
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 PRODUCTS OFFERED
  • 11.6.3 SWOT ANALYSIS
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGY
• 11.7 PFIZER, INC
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGY
• 11.8 ICECURE MEDICAL
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGY
• 11.9 ALPINION MEDICAL SYSTEMS
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 PRODUCTS OFFERED
  • 11.9.3 KEY DEVELOPMENTS
  • 11.9.4 SWOT ANALYSIS
  • 11.9.5 KEY STRATEGY
• 11.10 FUJIFILM HOLDINGS CORPORATION
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 PRODUCTS OFFERED
  • 11.10.3 KEY DEVELOPMENTS
  • 11.10.4 SWOT ANALYSIS
  • 11.10.5 KEY STRATEGY

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS

관련자료